drugset / Trial / NCT05118516
Safety, Tolerability, and Pharmacokinetics of ASC43F, a Fixed Dose Combination Tablet in Healthy Subjects
NaSingle-groupOpen-labelOther
Summary
This is a phase 1, open-label study in healthy adults. This study is aimed at evaluating the safety, tolerability, and pharmacokinetics of ASC43F, a fixed-dose combination (FDC) and single dose tablet containing ASC41, a THR β agonist and ASC42, an FXR agonist in healthy subjects.
Timeline
- Start
- 2021-11-01
- Primary completion
- 2021-12-07
- Completion
- 2021-12-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ASC41 | Unknown | 5 mg | Oral |
| Subject | ASC42 | Unknown | 15 mg | Oral |
Indications
No indication recorded.